DOH Abu Dhabi launches 1st UAE gene therapy clinical trial

Regulatory framework and site requirements

The Department of Health Abu Dhabi (DOH) initiated the United Arab Emirates’ first gene therapy clinical trial on 23 March 2026. This project shifts medical research in Abu Dhabi toward active interventional therapies. The trial follows the DOH’s 2025 research governance framework, which dictates how genomic data is stored in Abu Dhabi facilities. The Health Research Ethics Committee provides oversight for patient safety, enforcing standards set by the World Health Organization.

Economic scale and market impact

Gene therapy trials change the revenue potential for hospital operators in the UAE. Facilities hosting these trials generate higher research income and attract international medical staff. Abu Dhabi aims to increase its medical tourism market share by providing treatments that are currently unavailable elsewhere in the Middle East. The following indicators track the growth of this sector:

• Abu Dhabi hosts 60 active clinical research sites.
• The UAE genome program has processed 500,000 samples.
• Regional biotech investment reached AED 4.2 billion in 2025.

The initiation of this trial signals our intent to lead in precision medicine and reduce long-term reliance on external treatment centers for rare genetic conditions, said a DOH spokesperson.

Operational logistics for clinical directors

Clinical directors must upgrade facilities to handle cryogenic storage and specialized diagnostic suites for gene therapy. Hospitals that secure early-stage partnerships with international biotech firms can access the AED 900 million annual market for rare disease treatments in the UAE. High-level data security and interoperability remain the primary technical requirements for IT departments.

The Abu Dhabi Life Sciences Council provides incentives to lower operational barriers. Operators must calculate the return on investment for infrastructure costs against available government subsidies. Future trials will focus on hereditary conditions common in the regional population, specifically thalassemia and specific metabolic disorders. The success of this trial determines the next phase of the UAE healthcare strategy, which emphasizes domestic self-sufficiency in high-complexity care.